Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 1.00 |
| ▸ | ITGA4 | P13612 | 20/20 | 1.00 |
| ▸ | ITGA2 | P17301 | 1/20 | 1.00 |
| ▸ | ITGB7 | P26010 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641625 | 1.00 | ITGB1 (1.00) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL14802063 | 1.00 | ITGB1 (1.00) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6638294 | 0.99 | ITGB1 (0.98) | ITGB1ITGA4ITGA2ITGB7 | |
| Alcohol SCHEMBL6829612 | 0.97 | ITGB1 (0.94) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL29646297 | 0.94 | ITGB1 (0.88) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6639281 | 0.93 | ITGB1 (0.88) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7542199 | 0.93 | ITGB1 (1.00) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6828409 | 0.93 | ITGB1 (1.00) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6638576 | 0.93 | ITGB1 (0.92) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL6636796 | 0.93 | ITGB1 (0.86) | ITGB1ITGA4ITGA2ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | claimed |
| EP-1978928-B1 | PHARMACEUTICAL VALATOGRAST COMPOSITIONS AND PROCESS FOR MANUFACTURING THEM | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | claimed |
| EP-1005445-B1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | claimed |
| US-11964987-B2 | Isoidide derivatives and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20210002291-A1 | ISOIDIDE DERIVATIVES AND METHODS OF MAKING AND USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2021-01-07 | — | — | US | disclosed |
| US-10815244-B2 | Isoidide derivatives and methods of making and using same | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-27 | — | — | US | disclosed |
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-1154987-B1 | PHENYLALANINOL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-04-21 | — | — | EP | disclosed |
| EP-1403247-A1 | N-Alkanoylphenylalanine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-6420600-B1 | HYDROXYALKYLPHENYLDIAMIDES | HOFFMAN-LA ROCHE INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1154987-A1 | PHENYLALANINOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-21 | — | — | EP | disclosed |
| US-6229011-B1 | BINDING INHIBITORS BETWEEN VASCULAR ADHESION MOLECULE-1 AND ALPHA. BETA.INTEGRIN; USEFUL FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS MULTIPLE SCLEROSIS, ASTHMA, AND INFLAMMATORY BOWEL DISEASE | HOFFMAN-LA ROCHE INC. | 2001-05-08 | — | — | US | disclosed |
| CN-1281430-A | N-alkanoylphenylalanine derivatives | HOFFMANN LA ROCHE (CH) | 2001-01-24 | — | — | CN | disclosed |
| WO-2000048988-A1 | PHENYLALANINOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1005445-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010312-A1 | N-ALKANOYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964987-B2 | Isoidide derivatives and methods of making and using same | MIF, ITGB7, ITGB4 | ITGB1 17/4885ITGA4 5/4885ITGA2 70/4885 |
| US-10815244-B2 | Isoidide derivatives and methods of making and using same | MIF, ITGB7, ITGB4 | ITGB1 17/4885ITGA4 5/4885ITGA2 70/4885 |
| US-20210002291-A1 | ISOIDIDE DERIVATIVES AND METHODS OF MAKING AND USING SAME | MIF, ITGB7, ITGB4 | ITGB1 17/4885ITGA4 5/4885ITGA2 70/4885 |
| US-20170066778-A1 | SOLUBILITY FOR TARGET COMPOUNDS | MIF, ITGB7, ITGB4 | ITGB1 10/4885ITGA4 4/4885ITGA2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.